Interview with Polepharma

1. What do you think will be the biggest trends in the pharmaceutical and biopharmaceutical industry for 2022?

The biggest trends for 2022 are the development of new solutions for major challenges such as illness, and damage to the environment. Personalized medicine will be a strong focus throughout 2022, and researchers are confident it will lead to more effective and efficient treatments for many diseases.
2022 will undoubtedly also see further debate around the ethics of biotechnology.
Drug development is a long-term process that requires patience and persistence. Only companies that are committed to investing in innovation can benefit from the long-term opportunities. The innovations by technological approaches could transform drug research in 2022. Innovation-driven companies with strong balance sheets, real capability to strong R&D, and benefiting from long-term structural growth have a serious advantage in this domain.
The pharma industries have been cautious to embrace digital technologies than many less-regulated sectors. But the COVID-19 pandemic has changed the equation, making pharma companies more open-minded. For sure, in the future, this new transition with new technologies will continue and progress. In 2022, a growing number of pharmaceutical companies will recognize how their products could significantly improved outcomes with a digital component.
The digitization, digital transformation or Manufacturing 4.0 will be one of the key areas of investment for years to come. The potential is enormous, in particular thanks to Artificial Intelligence, whether for research (image processing, new drugs, clinical trials, etc.), industrialization (predictive maintenance, optimization of processes via IA, etc.) up to the patient (connected patients, individualized treatments based on patient characteristics, etc.). Pharmaceutical companies invest heavily in this areas, you just need to see the new profiles sought: data scientist, data engineer, data analyst, etc. which was not the case 5 or 10 years ago.
Companies are now aware that they risk missing market opportunities if they wait for the development of enterprise solutions. By the same approach, a growing number of studies will allow more flexibility with digital components in how patients choose to participate : the virtually handling options are an effective way to engage patients successfully.

2. The pharma industry has been pivotal during the pandemic, do you think this will continue into 2022?

Awaiting the emergency development and approval of Covid-19 vaccinations, huge efforts have been made to speed up the process of testing and approving new drugs. Faster pharmaceutical testing and approval of medicines will be vital. By the way, these new product developments will make the pharma industry as a major activity sector. And the biotech industry will find their way there, since biotech data is being used to speed up this process by allowing simulations of interactions between medicines and the human body, rather than having to rely on costly and time-consuming human trials for every stage of the process.

3. How will Covid -19 affect the pharma industry in 2022?

We can hope that the COVID-19 will no longer be here towards the end of 2022, but meanwhile drug developers and pharmaceutical companies will use this experience.
Next year, the pharmaceutical industry will benefit from new insights in understanding patients and diseases thanks to advances in machine learning and computer vision, in research and development. As far as we can be prospective, we can assume that COVID will still be in everyone’s mind all year long.
The global pandemic has accelerated both the development and adoption of biotech and thanks to it, we are more reactive and more able to target effective therapies for patients, able to develop faster new products and lead new clinical studies with accelerated results.

4. What will be the new packaging innovation or product in the pharma and biotech industry in 2022?

For sure, innovation about packaging should be environmentally friendly, and should include new processes involving creating clean energy from industrial waste and being biodegradable. But that’s not so easy!
Many certificates are now available to ensure customers that companies are clean manufacturers.
But there are many more challenges such as integrated packaging design for a more sustainable pharma future, new innovations and brand protection, increasing the flexibility and reliability of the supply chain in new realities, taking costs into account, quality and product safety.

Follow us:

Share this article:

Share on linkedin
LinkedIn

Sign Up to our newsletter

What are they signing up yo with the newsletter?

At Easyfairs, we take your privacy seriously and will only use the information we collect or receive about you in accordance with our privacy policy. If you change your mind you can unsubscribe at any time.